Companies › InSightec
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jun 2031.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Blood Brain Barrier Opening - Oncology (Exablate BBBO) Blood-brain barrier opening via focused ultrasound with microbubbles | – | Phase 3 | Brain Tumor | Jun 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05317858 | Blood Brain Barrier Opening - Oncology (Exablate BBBO) | Phase 3 | Brain Tumor | Oncology | Jun 2031 |
No annotated target.
–
SynOx Therapeutics NingBo Junyan Hongshi Biosciences Taizhou Hanzhong biomedical NovoCure Summit Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.